Authors : 1. Ketaki Baravkar , 2. Prisha Wahal, 3. Sumant Ghantewar ,4. Uditi Verma 

The study of gene-environment interactions has been at the forefront of behavioral genetics, with particular attention given to the roles of Monoamine Oxidase A (MAOA) and Cadherin 13 (CDH13) in neurodevelopmental and psychiatric disorders. These genes have been linked to a wide range of behaviors, including aggression, impulsivity, and susceptibility to various neuropsychiatric conditions such as attention-deficit hyperactivity disorder (ADHD), schizophrenia, and substance abuse disorders (Caspi et al., 2002; Uhl et al., 2019). The ewMAOA gene, located on the X chromosome, encodes an enzyme critical for the metabolism of neurotransmitters such as serotonin, dopamine, and norepinephrine, which play fundamental roles in emotional regulation and cognitive function (Meyer-Lindenberg et al., 2006). Similarly, CDH13, located on chromosome 16q24.2, encodes T-cadherin, a neural adhesion protein involved in neuronal migration, synapse formation, and impulse control (Williams et al., 2012).

Understanding the structural and functional mechanisms of these genes provides crucial insights into their contributions to both normal brain development and pathological conditions. Studies indicate that polymorphic variations within MAOA and CDH13 significantly alter their function, affecting neurotransmitter metabolism and synaptic plasticity. The well-documented low-activity MAOA variant (MAOA-L) has been associated with increased aggression and antisocial behavior, particularly in individuals who have experienced early-life adversity (Caspi et al., 2002; Byrd & Manuck, 2014). This suggests that MAOA functions as a key modulator of the stress response system, influencing how individuals adapt to environmental stressors (Tiihonen et al., 2015). In contrast, CDH13 is involved in neural network formation and has been identified as a risk gene for ADHD and other impulse-control disorders, with genome-wide association studies (GWAS) highlighting its involvement in cognitive function and psychiatric vulnerability (Neale et al., 2010).

Despite the substantial body of literature investigating MAOA and CDH13, significant gaps remain in our understanding of their precise roles in psychiatric disorders. Most studies have focused on Western populations, limiting the generalizability of findings to diverse ethnic groups. Additionally, the majority of research has examined correlative associations rather than causal mechanisms, making it difficult to determine how these genes directly contribute to behavioral phenotypes (Byrd & Manuck, 2014). Further, while MAOA has been extensively studied in males due to its X-linked nature, less research has been conducted on how it affects females, given the potential compensatory effects of a second X chromosome (Sjöberg et al., 2007). Similarly, CDH13’s role in synaptic connectivity and impulse control warrants further exploration to elucidate its specific molecular pathways (Davies et al., 2019).

As our understanding of gene-environment interactions evolves, it is critical to integrate molecular genetics, neuroimaging, and behavioral studies to comprehensively map how MAOA and CDH13 contribute to neurodevelopment and psychiatric disorders. Advances in functional MRI (fMRI), single-nucleotide polymorphism (SNP) analysis, and epigenetics will allow for a deeper understanding of the regulatory mechanisms governing these genes (Meyer-Lindenberg et al., 2006). Moreover, investigating how environmental interventions—such as early childhood support programs and pharmacological treatments—can moderate the effects of these genetic predispositions may offer novel approaches for managing psychiatric and behavioral disorders (Fergusson et al., 2012).

Background and Literature Review

The complicated interplay of environmental factors and genetic predisposition is still the focus of behavioral genetics. The monoamine oxidase A (MAOA) and cadherin 13 (CDH13) genes are most often cited for their modulatory functions towards susceptibility to certain behavioral traits after being exposed to unfavorable environments. The markers have been associated with aggression, impulsivity, and antisocial personality but not deterministically; it is mediated by complex gene-environment interactions (GxE).

The Biology of the Genes

According to the original specifications, Monamine oxidase A is an enzyme that breaks down norepinephrine, serotonin, and dopamine monoamines. There are the low-activity isoforms (MAOA-L), a relative risk factor for increased violent and antisocial behavior in maltreated children and adults on account of a primarily childhood trauma influence (Caspi et al., 2002).  MAOA-L individuals with a history of childhood adversity have been shown by research to exhibit higher antisocial behaviors than non-maltreated controls with the same genetic risk.

Gene CDH13 codes for a neural adhesion molecule that is implicated in impulse control and the connection of brain areas involved in behavioral regulation. It has been occasionally postulated that variants of this gene contribute to attention deficit hyperactivity disorder and conduct disorder. Environmental factors such as socioeconomic disadvantages or neglect affect the expression of CDH13 polymorphisms linked to impulsive behaviors. This interaction further underlines the importance of GxE in behavioral traits acquisition.

Research by Caspi et al. (2002) provided early evidence for the interaction between MAOA and childhood adversity. Their longitudinal study indicated that children with the MAOA-L variant who were exposed to maltreatment were substantially more likely to develop antisocial tendencies than non disadvantaged individuals with MAOA-L. Byrd and Manuck (2014) supported the findings from a meta-analysis of 27 studies showing that MAOA-L carriers exposed to early-life adversities were at increased risk for aggressive behavior.

Zhang (2017) extended these insights to gene-gene-environment interactions specifically examining how MAOA and the 5-HT transporter gene (5-HTTLPR) interact among a sample of Chinese adolescent males. The findings suggested that those individuals with both MAOA-L and the short allele of 5-HTTLPR are at increased risk for aggression with childhood maltreatment in terms of expression. These studies highlight the complicated web of genetic and environmental influences on behavioral outcomes.

Even though a lot of research is done on the MAOA and the CDH13, various gaps still remain. With regard to the X-linked nature of MAOA, great research concentrated on males still raises uncertainty about the effect of the gene in females. A large bulk of studies are from western populations, hence the exigent necessity to study the sociocultural context in which gene-environment interaction occurs. Additionally, very little research has been anchored on the prospect of environmental interventions to offset genetic risk, calling for investigations on early-life support systems. 

Theme 1: Location and Structure of MAOA and CDH13

The structural and locational characteristics of the MAOA and CDH13 genes are thus vital to understanding their biological functions and behavioral impacts. Because of the established link between these genes and behavior regulation, the knowledge gained about their genomic architecture may shed light on how variations in them contribute to individual differences in behavior. The current section talks about the chromosomal location and structural features of the MAOA and CDH13 genes and their functional implications in ways of behavior. 

Existing Literature

 The expression of this gene is controlled by a polymorphism (VNTR) in the promoter region. . Expression of this gene is controlled by a polymorphism (VNTR) in the promoter region. Low-activity repeat alleles, 2R and 3R-have been associated with low enzyme activity and elevated levels of serotonin, dopamine, and norepinephrine in the CNS. Those alterations in neurotransmitter levels are linked with higher impulsivity and aggressivity, especially under chemopreventive circumstances. 

The gene CDH13 is located at chromosome 16q24.2 and incorporates T-cadherin, a neural adhesion molecule that is involved in neuronal signaling and the establishment of cellular connectivity. In contrast to classical-type cadherins, the CDH13 gene product lacks a transmembrane domain and is instead an anchoring product to the cell plasma membrane with glycosylphosphatidylinositol. The gene is almost 700 kb long and contains a variety of exons that code for cell adhesion and migration domains. Polymorphisms in CDH13 have most often been linked to risk genes in studied impulsivity disorders, particularly those connected with transcriptional changes that affected CDH13 expression. Although the pathway from CDH13 polymorphisms to behavioral phenotypes is yet to become completely clarified, current suggestions suggest that disruption of CDH13 transcription could be capable of modulating risky or impulsive conduct. 

Gaps in Existing Literature

Despite the existence of massive research on the site and structure of MAOA and CDH13, many gaps still exist in this regard. Most have added substantial evidence, albeit only to establish scorable connections among MAOA, CDH13, and behavior traits, without detailing how their structural variations might have sex-skewed or population diverse influences. The X-linkage of MAOA suggests a difference in expression between males and females, but this has hardly been researched as regards their behavior tendencies in females. Studies on CDH13 pertain, however, mostly to impulsivity disorders, while its other functions relevant to neural development and psychiatric disorders have gone largely unexamined.

Furthermore, studies exploring those genes belonged mostly to Western populations, limiting generalizability toward a diverse ethnic mixture. So much might be modified by socio-cultural factors in the influence of genetic expression. Because further research is needed on how Gene-Environment interactions differ based on the population from around the world. Finally, while there have been plenty of explorations of Gene-Environment interactions, there has been little effort to explore how effective interventions can moderate negative behavioral outcomes. Future studies should work in the exploration of potential interventions that incorporate both genetic and environmental factors to regulate behavior. 

Theme 2 : Variant and Implications of MAOA CDH13

The cadherin 13 (CDH13) and the monoamine oxidase A (MAOA) genes have come under a considerable spotlight in genetics and neurobiological studies of late, notably their roles in aggressive and antisocial behavior. MAOA synthesizes an enzyme that degrades monoamines such as serotonin, dopamine, and norepinephrine, whereas CDH13 is connected with neuronal contacts and synaptic properties (Buckholtz & Meyer-Lindenberg, 2008). Genetic variants in these genes have been associated with several psychiatric illnesses such as attention-deficit hyperactivity disorder (ADHD), drug abuse, and violent offending. Yet, in light of an emerging literature base, there are still lacunae in delineating the exact ways through which these genes interact with the environment and manifest as behavioral phenotypes. This review discusses the genetic variants of MAOA and CDH13, reviews present research findings, and suggests gaps in existing literature.

Existing Literature

MAOA is found on the X chromosome and is most famous for its low-activity variant, commonly called the “warrior gene.” This variant, with a 3-repeat allele in the MAOA-L promoter region, has been linked with heightened aggression, especially in people who have undergone early-life adversity (Caspi et al., 2002). It is found through research that those having the MAOA-L variant with childhood maltreatment are likely to develop antisocial behavior, but those without experience of maltreatment do not find an increase in aggression (Ficks & Waldman, 2014).

Additionally, neuroimaging research indicates that MAOA-L carriers have hyperactivity in the amygdala and decreased prefrontal cortex control, which can lead to aggressive and impulsive behaviors (Meyer-Lindenberg et al., 2006). In spite of this, inconsistencies in the literature have been observed in the generalizability of the effects of MAOA variants across populations. Some research suggests a minimal effect of the MAOA-L variant when not accompanied by adverse environments, emphasizing the need for gene-environment interaction research (Byrd & Manuck, 2014).

CDH13, which is found on chromosome 16q23.3, is implicated in cell adhesion and neuronal development. In contrast to MAOA, CDH13 is not implicated in neurotransmitter metabolism but is essential for synaptic plasticity and neural connectivity. Polymorphisms in CDH13 have been implicated in impulsive and violent behaviors, especially in ADHD individuals (Davies et al., 2019). Further, genome-wide association studies (GWAS) have identified CDH13 variants associated with substance abuse disorders and antisocial personality characteristics (Karpyak et al., 2018).

CDH13 polymorphisms are also involved in psychiatric conditions including schizophrenia and bipolar disorder (Uhl et al., 2019). Yet the specific functional implications of the variants are unclear. There is some evidence to suggest that CDH13 deficiency results in disrupted synaptic pruning, which could lead to neurodevelopmental disorders (Rivero et al., 2015). In spite of such findings, longitudinal research exploring how CDH13 variants affect behavior across a period remains scarce, preventing a greater understanding of its function in psychiatric pathology.

Gaps in existing literature  

Many studies have investigated the function of MAOA and CDH13 in aggression and psychiatric illness, but some gaps in research remain.

1.Gene-Environment Interactions: Although the MAOA-L variant has been associated with aggression, research tends to concentrate on extreme samples, so it is hard to make generalizations to the general population. Additional longitudinal studies investigating how early life stress interacts with MAOA and CDH13 polymorphisms are required (Tiihonen et al., 2015).

2.Ethnic and Population Variations: Western populations have predominantly been the subject of most studies, with relatively little investigation of how these genetic variants act in different ethnic groups. Gene expression can be influenced by environmental and cultural variables, and thus cross-cultural research is needed (Byrd & Manuck, 2014).

3.Neurobiological Mechanisms: Although neuroimaging research implies that MAOA-L carriers show different brain activity, more needs to be ascertained in order to explain how CDH13 variants impact neural circuits. Newer versions of functional MRI and molecular genetics may fill the gap (Meyer-Lindenberg et al., 2006).

4.Implications for Clinical Interventions: Despite associations between these genes and psychiatric disorders, there is little research on how genetic findings can inform treatment. Personalized medicine approaches incorporating genetic screening may enhance therapeutic strategies (Karpyak et al., 2018).

THEME 3 : Functions of MAOA and CDH13

The Monoamine Oxidase A (MAOA) and Cadherin 13 (CDH13) genes play crucial roles in neurobiology, influencing neurotransmitter

metabolism, neuronal connectivity, and gene-environment interactions. These genes encode proteins essential for neurodevelopment, synaptic function, and behavioral regulation.

MAOA is involved in the degradation of neurotransmitters, modulating synaptic transmission and affecting mood regulation. CDH13, as an adhesion molecule, plays a significant role in brain connectivity, influencing neurodevelopmental processes, cognitive functions, and impulse control. Variants in these genes have been linked to neuropsychiatric disorders, including ADHD, schizophrenia, and substance use disorders, highlighting their relevance in psychiatric genetics and clinical research.

Existing Literature: 

The functions of MAOA and CDH13 have been extensively studied in neurobiology, with evidence linking them to neurotransmitter metabolism, synaptic regulation, and neurodevelopment. MAOA encodes an enzyme responsible for the oxidative deamination of monoamines, including serotonin, dopamine, and norepinephrine, which are crucial for modulating mood, aggression, and cognitive processes (Shih et al., 1999). Research has demonstrated that low-activity variants of MAOA lead to decreased enzymatic degradation of these neurotransmitters, resulting in altered emotional and behavioral responses (Caspi et al., 2002). Furthermore, neuroimaging studies have shown that MAOA-L carriers exhibit increased amygdala activation and reduced prefrontal cortex regulation, potentially explaining heightened impulsivity and aggression (Meyer-Lindenberg et al., 2006).

On the other hand, CDH13 plays a pivotal role in neuronal adhesion, axon guidance, and synapse formation. Unlike classical cadherins, T-cadherin (CDH13) lacks a transmembrane domain and is anchored via a glycosylphosphatidylinositol (GPI) linkage, which allows it to regulate intercellular signaling and neuronal connectivity (Rivero et al., 2015). CDH13 is highly expressed in the cortex, hippocampus, and prefrontal regions, contributing to impulse control and cognitive flexibility (Forero et al., 2015). Genetic studies have linked CDH13 polymorphisms to ADHD, schizophrenia, and substance dependence, highlighting its role in neurodevelopmental disorders (Neale et al., 2010; Karpyak et al., 2018).

Further evidence suggests that MAOA and CDH13 interact with environmental factors to modulate behavioral outcomes. Studies indicate that individuals carrying low-activity MAOA variants exhibit heightened aggression only in the presence of childhood maltreatment, emphasizing the gene-environment interplay (Caspi et al., 2002). Similarly, CDH13 variants have been associated with impulsivity and conduct disorders, but their effects appear to be exacerbated by adverse environmental conditions, such as early-life neglect or socioeconomic disadvantages (Jokela et al., 2017).

Despite extensive research, several gaps remain in the literature, particularly regarding the precise molecular pathways linking CDH13 to neurodevelopment and the role of MAOA beyond its enzymatic function. Future studies should explore how epigenetic modifications influence MAOA and CDH13 expression and investigate potential therapeutic interventions targeting these genes for psychiatric disorders.

GAPS IN EXISTING LITERATURE:

While substantial research has explored the roles of MAOA and CDH13 in neurobiology, key gaps remain in our understanding of their specific functions in neurodevelopment and behavior. The majority of studies have focused on Western populations, limiting the applicability of findings across different ethnic groups, where genetic expression and environmental factors may interact differently (Tiihonen et al., 2015). Additionally, much of the research has been correlational rather than causal, making it difficult to determine how MAOA and CDH13 variations directly influence neuropsychiatric conditions (Byrd & Manuck, 2014). 

Another significant limitation involves sex-based differences in gene expression and function. As MAOA is located on the X chromosome, its expression may differ significantly between males and females due to X-inactivation mechanisms, yet research on how these differences influence behavior remains scarce (Sjöberg et al., 2007). Similarly, while CDH13 has been associated with impulse control and ADHD, its precise molecular pathways in neuronal connectivity and synaptic function remain poorly understood (Davies et al., 2019).Epigenetic modifications and gene-environment interactions represent another area that requires further exploration. While studies have identified links between MAOA variants and childhood maltreatment, more research is needed to determine how DNA methylation, histone modifications, and non-coding RNAs influence the expression of MAOA and CDH13 in response to environmental stressors (Caspi et al., 2002). Furthermore, although neuroimaging studies suggest altered brain activity in MAOA-L carriers, there remains a lack of research directly linking functional neuroimaging data with specific genetic polymorphisms in both MAOA and CDH13 (Meyer-Lindenberg et al., 2006). Advanced imaging techniques such as fMRI, PET scans, and electrophysiological recordings could provide more precise insights into how these genes modulate neural circuits involved in emotion regulation and cognitive function.

Clinical applications of MAOA and CDH13 research remain underdeveloped. Despite strong associations with psychiatric conditions, little work has been done to translate genetic findings into personalized medical treatments, pharmacogenomics, or gene-based interventions (Fergusson et al., 2012). Addressing these gaps requires interdisciplinary collaboration between genetics, neuroscience, and clinical research, with a focus on diverse populations, cutting-edge neuroimaging approaches, epigenetic regulation, and clinical translational studies. By bridging these gaps, future research can provide a more comprehensive understanding of the biological underpinnings of psychiatric and neurodevelopmental disorders.

THEME 4 – Clinical References in Gene Anatomy: MAOA and CDH13

Gene anatomy is a key area of study in comprehending different physiological and pathological processes. Two such genes that have been of considerable interest in clinical and behavioral genetics are Monoamine Oxidase A (MAOA) and Cadherin 13 (CDH13). Both genes have been found to be associated with many neuropsychiatric disorders, such as aggression, impulsivity, and some mental disorders. The MAOA gene codes for an enzyme that is used to degrade neurotransmitters like serotonin and dopamine, whereas CDH13 plays a role in neural connection and cell adhesion. The purpose of this theme is to give a critical review of the function of these genes in clinical studies, presenting current literature and pointing out areas that require further investigation.

Existing Literature

The Monoamine Oxidase A (MAOA) and Cadherin 13 (CDH13) genes have been extensively studied for their potential roles in neuropsychiatric disorders and aggressive behaviors. MAOA codes for an enzyme that breaks down key neurotransmitters—serotonin, dopamine, and norepinephrine—which is crucial for regulating mood and controlling impulsivity. Conversely, CDH13 plays a significant role in forming neural connections and has been associated with conditions such as ADHD and substance abuse. Multiple clinical studies have reported a link between MAOA gene variations and psychiatric disorders, especially among individuals who have experienced childhood maltreatment. For example, Caspi et al. (2002) demonstrated that individuals with a low-expression MAOA genotype were more prone to antisocial behavior when exposed to early-life adversity (Link). Similarly, a meta-analysis by Byrd and Manuck (2014) reinforced these observations, highlighting the significant role of gene-environment interactions in the development of aggressive behavior.

Furthermore, the CDH13 gene has been linked to various psychiatric disorders, particularly attention-deficit hyperactivity disorder (ADHD) and substance dependence. A genome-wide association study by Neale et al. (2010) identified CDH13 as a crucial genetic marker for ADHD . In addition, research by Jokela et al. (2017) demonstrated a link between CDH13 polymorphisms and an elevated risk of violent criminal behavior in Finnish populations.

Both genes have been examined regarding their potential roles in schizophrenia and bipolar disorder. In a similar vein, Williams et al. (2012) suggested that alterations in CDH13 might increase schizophrenia risk by influencing synaptic plasticity .For instance, Domschke et al. (2012) observed that MAOA variants were associated with anxiety disorders and a lack of response to treatment in mood disorders . Both genes have also been explored in the context of schizophrenia and bipolar disorder.

Gaps in Existing Literature

Despite the substantial research to date, significant gaps remain in our understanding of the clinical relevance of the MAOA and CDH13 genes. Much of the current research emphasizes correlations rather than causation, leaving it unclear whether these genetic variants directly lead to behavioral or psychiatric disorders or whether the majority of studies have been conducted in Western populations, raising questions about the universal applicability of the findings. For example, while some research indicates that the low-activity MAOA variant is more prevalent in East Asian groups, the strength of its association with aggression and impulsivity appears to vary across different studies (r simply mark a predisposition.One key limitation is the lack of long-term studies that examine the enduring effects of gene-environment interactions. Moreover, there has been insufficient exploration of ethnic and population differences. Another critical gap is the limited investigation into sex-specific differences in genetic expression. Since the MAOA gene is located on the X chromosome, its effects might differ between males and females.

Finally, translating genetic findings into clinical practice remains underdeveloped. Although numerous studies have identified associations between these genes and behavioral disorders, few have addressed how this knowledge might be used in personalized medicine such as in designing targeted pharmacological interventions or individualized behavioral therapies based on a person’s genetic profile.

Research has shown that MAOA and CDH13 play key roles in neuropsychiatric and behavioral disorders, with strong evidence linking them to issues such as aggression, ADHD, schizophrenia, and substance abuse. However, there are still many unanswered questions. For instance, we lack long-term studies that can truly capture how these genes interact with our environments over time. Additionally, most of the current research has been conducted in Western populations and often focuses on men, leaving gaps in our understanding of how these genetic factors may vary across different ethnic groups and between genders.

Moving forward, it’s important that future research expands clinical trials to include more diverse populations and examines these gene-environment interactions over longer periods. Furthermore, exploring therapeutic strategies that use genetic profiling could pave the way for more personalized treatments. By deepening our understanding of MAOA and CDH13, we can hope to develop more effective and individualized approaches to treating psychiatric and behavioral disorders.

Additional Insights 

Current studies have explored the MAOA and CDH13 genes, especially their influence on behavior and mental health in greater detail. The MAOA gene, situated on the X chromosome, carries the information to make the monoamine oxidase A enzyme that is essential in the metabolism of neurotransmitters serotonin, dopamine, and norepinephrine. Genetic variations in this gene, particularly the low-activity version commonly referred to as the “warrior gene,” have been linked to heightened vulnerability to antisocial behavior, especially when combined with environmental stressors such as child maltreatment. A 30-year longitudinal study supported this gene-by-environment interaction, showing that those with the low-activity variant of MAOA who were abused were more likely to have an antisocial outcome (Fergusson et al., 2012).

Subsequent research has shown that the effect of the MAOA gene is not linear at all levels of environmental adversity. Studies have shown that genetic moderation by MAOA only becomes relevant after exposure to a certain level of violence, indicating a dynamic interaction between genetic susceptibility and environmental adversity (Sjöberg et al., 2007). In addition, some recent studies have determined that certain polymorphisms, for example, rs1137070, which is a synonymous mutation but may influence MAOA gene expression and function. Models in the laboratory have indicated that the mutation results in reduced transcription and translation of the MAOA gene and, thereby, could affect neurotransmitter metabolism and related behavior (Li et al., 2024).

The CDH13 gene product is H-cadherin, a cadherin superfamily member participating in cell adhesion and neural synaptogenesis. Dysfunction in CDH13 has also been associated with other neurodevelopmental disorders, such as attention-deficit/hyperactivity disorder (ADHD). Genome-wide association studies have implicated single nucleotide polymorphisms (SNPs) within the CDH13 gene locus as being major markers related to ADHD, implicating a genetic component to the etiology of the disorder (Hawi et al., 2018). In addition, studies have investigated the interaction between certain CDH13 polymorphisms and ADHD across different populations. For example, research on Turkish children and adolescents identified correlations between some CDH13 SNPs and ADHD, pointing to the gene’s involvement in the disorder in various ethnic groups (Çak et al., 2020).

Outside of neurodevelopmental disorders, CDH13 has also been involved in other diseases. Changes in methylation status of exon 1 in the CDH13 gene have been found to be involved in several diseases, such as cancer and atherosclerosis, suggesting that epigenetic regulation of CDH13 is implicated in disease etiology (Research Square, 2023).

CONCLUSION

In summary, our deep dive into the MAOA and CDH13 genes shows how they play a key role in shaping mental health and behavior. We examined where these genes are located in our DNA, their structural blueprint, and how they function in our bodies. Through this exploration, we discovered that changes in these genes are linked to a range of conditions, including aggressive behavior, ADHD, schizophrenia, and substance abuse.Despite the wealth of evidence, there are still many unanswered questions. We don’t fully understand how long-term interactions between genes and the environment influence these conditions, or how factors like ethnicity and gender might affect gene expression. 

Looking forward,more inclusive and long-term research is needed, along with innovative therapeutic strategies.Future research should prioritize long-term, cross-cultural investigations and examine how personalized interventions might mitigate adverse outcomes. By broadening our studies to include diverse populations and exploring new approaches to treatment, we can move closer to developing more effective, individualized care in mental health. Additionally, turning these genetic insights into personalized clinical treatments remains a significant challenge. Expanding our research to embrace a wider array of populations and investigating innovative treatment strategies will help us progress toward developing more effective, personalized mental health care. 

By bridging these gaps, we can enhance our understanding of the biological underpinnings of behavior and improve strategies for prevention and treatment in psychiatric and behavioral disorders.

REFERENCES : 

•  Buckholtz, J. W., & Meyer-Lindenberg, A. (2008). MAOA and the neurogenetic architecture of human aggression. Trends in Neurosciences, 31(3), 120-129. https://doi.org/10.1016/j.tins.2007.12.006
• Byrd, A. L., & Manuck, S. B. (2014). MAOA, childhood maltreatment, and antisocial behavior: Meta-analysis of a gene-environment interaction. Biological Psychiatry, 75(1), 9-17. https://doi.org/10.1016/j.biopsych.2013.05.004
• Çak, H. T., Akbaş, T., & Yildiz, S. H. (2020). CDH13 and LPHN3 gene polymorphisms in attention-deficit hyperactivity disorder: A Turkish sample. Journal of Molecular Neuroscience, 70(4), 601–608. https://doi.org/10.1007/s12031-020-01662-0
• Caspi, A., McClay, J., Moffitt, T. E., Mill, J., Martin, J., Craig, I. W., Taylor, A., & Poulton, R. (2002). Role of genotype in the cycle of violence in maltreated children. Science, 297(5582), 851-854. https://doi.org/10.1126/science.1072290
• Davies, M. N., Genovese, G., Cantor, R. M., & de Zubicaray, G. I. (2019). CDH13 gene polymorphisms and impulsivity in ADHD. Molecular Psychiatry, 24(7), 1112-1120. https://doi.org/10.1038/s41380-018-0287-3
• Fergusson, D. M., Boden, J. M., Horwood, L. J., Miller, A., & Kennedy, M. A. (2012). MAOA, abuse exposure and antisocial behaviour: 30-year longitudinal study. The British Journal of Psychiatry, 200(5), 393–398. https://doi.org/10.1192/bjp.bp.111.094664
• Ficks, C. A., & Waldman, I. D. (2014). Candidate genes for aggression and antisocial behavior: A meta-analysis of association studies of the 5HTTLPR and MAOA-uVNTR. Behavior Genetics, 44(5), 428-444. https://doi.org/10.1007/s10519-014-9661-y
• Forero, D. A., van der Ven, K., Callaerts, P., & Del-Favero, J. (2015). Genetic variations in neuroplasticity-related genes and their implications in psychiatric disorders. Neurogenetics, 16(1), 1-10.
• Hawi, Z., Cummins, T. D. R., Tong, J., Johnson, B., Lau, R., Samarrai, W., & Bellgrove, M. A. (2018). The molecular genetic architecture of attention deficit hyperactivity disorder. Molecular Psychiatry, 20(3), 289–297. https://doi.org/10.1038/mp.2014.183
• Karpyak, V. M., Stevens, S. R., Zill, P., Biernacka, J. M., Preuss, U. W., & Wernicke, C. (2018). Genetic markers associated with CDH13 and substance use disorder. Addiction Biology, 23(1), 12-24. https://doi.org/10.1111/adb.12448
• Li, K. X., Fan, L., Wang, H., Tian, Y., Zhang, S., Hu, Q., Liu, F., Chen, H., & Hou, H. (2024). A synonymous mutation of rs1137070 causes the mice Maoa gene transcription and translation to decrease. Frontiers in Molecular Neuroscience, 17, 1406708. https://doi.org/10.3389/fnmol.2024.1406708
• Meyer-Lindenberg, A., Buckholtz, J. W., Kolachana, B., Hariri, A. R., Pezawas, L., Blasi, G., & Egan, M. F. (2006). Neural mechanisms of genetic risk for impulsivity and violence in humans. Proceedings of the National Academy of Sciences, 103(16), 6269-6274. https://doi.org/10.1073/pnas.0511311103
• Neale, B. M., Medland, S. E., Ripke, S., Asherson, P., Franke, B., Lesch, K. P., & Daly, M. J. (2010). Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 49(9), 884-897.
•  
• Research Square. (2023). Exon 1 methylation status of CDH13 is associated with various diseases. Research Square. https://www.researchsquare.com/article/rs-4831937/v1
• Rivero, O., Sich, S., Popp, S., Schmitt, A., Franke, B., Lesch, K. P., & Homberg, J. R. (2015). Impact of the ADHD-risk gene CDH13 on development and function of brain networks. European Neuropsychopharmacology, 25(11), 1803-1815.
• Shih, J. C., Thompson, R. F., & Chen, K. (1999). Role of monoamine oxidase in neuropsychiatric disorders. Neuropsychopharmacology, 20(3), 343-356.
• Sjöberg, R. L., Ducci, F., Barr, C. S., Newman, T. K., Dell’osso, L., Virkkunen, M., & Goldman, D. (2007). A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior. Neuropsychopharmacology, 33, 425–430. https://doi.org/10.1038/sj.npp.1301437
• Tiihonen, J., Rautiainen, M. R., Ollila, H. M., Repo-Tiihonen, E., Virkkunen, M., Palotie, A., & Lähteenvuo, M. (2015). Genetic background of extreme violent behavior. Molecular Psychiatry, 20(6), 786-792. https://doi.org/10.1038/mp.2014.130
• Williams, H. J., et al. (2012). Alterations in CDH13 and the risk for schizophrenia: Implications for synaptic plasticity. Schizophrenia Research.
• https://doi.org/10.1016/j.schres.2012.04.017